Cancer’s Genetic Signature
Dr. Green is the director of the National Human Genome Research Institute, one of the 27 institutes and centers that make up the U.S. National Institutes of Health, the federal agency that funds and conducts medical research. The NIH Intramural Sequencing Center is a lab that Dr. Green founded and which is part of the National Human Genome Research Institute.
Prior to this appointment, he was the Scientific Director of NHGRI, a position he held since 2002. In addition, Green serves as chief of the NHGRI Genome Technology Branch (since 1996) and director of the NIH Intramural Sequencing Center (NISC) (since 1997).
Eric Green: So cancer is fundamentally a disease of the genome. I mean the reason a tumor grows is because the cells in that tumor have picked up glitches. They picked up mutations. They picked up changes in the DNA that make those cells grow out of control. It’s like pressing an accelerator in a car and just keep it going. It just grows and grows and grows and grows. And the reason why is because something’s broken in the genome. And so what’s happened in the past ten years in particular since the end of the Human Genome Project is the recognition that we can read out the genome, the sequence of the tumor’s DNA and gain insights from that tumor with respect to what had been the DNA changes that have led to those cells becoming a cancer.
And that is being done on a very large scale in many countries around the world and here including the United States where literally very defined cancers are being studied. Hundreds of specimens are being collected from people and those genomes of those tumors are being read out and have all that data be put on the Internet for scientists to be able to collect it all and analyze it. And we are learning a tremendous amount about cancer in many very interesting and surprising ways. And among the many things that are happening is it’s giving us insights about how to better classify different types of cancer and different subtypes of cancer. And I often make the point that some of the earliest implementation of genomics in the medical situation is gonna be with cancer.
And it’s already happening now and I think it’s gonna grow considerably. Where I think standard of care for many types of cancer are gonna be get that tumor, read out it’s DNA, sequence it’s genome and based on what you’ve seen what’s wrong with that tumor, not by looking at it under a microscope only or by looking at it in a sort of a gross fashion but actually looking inside it’s blueprint, you will be able to have a much better way of deciding what types of treatments to pursue and have a much better idea about what’s wrong in that kind of tumor. And some of those things will also be very helpful for leading to possibly new developments of therapies.
Directed/Produced by Jonathan Fowler and Dillon Fitton
Cancer is fundamentally a disease of the genome. What has happened in the past ten years since the end of the Human Genome Project is the recognition that we can read out the genome, and read the sequence of a tumor’s DNA and gain insights from that tumor.
A new study estimated the untapped potential of wind energy across Europe.
- A new report calculated how much electricity Europe could generate if it built onshore wind farms on all of its exploitable land.
- The results indicated that European onshore wind farms could supply the whole world with electricity from now until 2050.
- Wind farms come with a few complications, but the researchers noted that their study was meant to highlight the untapped potential of the renewable energy source in Europe.
French newspapers report that the trial hasn't lived up to expectations.
- The French government initially invested in a rural solar roadway in 2016.
- French newspapers report that the trial hasn't lived up to expectations.
- Solar panel "paved" roadways are proving to be inefficient and too expensive.
You want one. Now you may be able to survive one.
Photo credit: Jie Zhao / Getty contributor
- Cats live in a quarter of Western households.
- Allergies to them are common and can be dangerous.
- A new approach targets the primary trouble-causing allergen.